Resmed Inc
NYSE:RMD

Watchlist Manager
Resmed Inc Logo
Resmed Inc
NYSE:RMD
Watchlist
Price: 243.78 USD 0.01% Market Closed
Market Cap: 35.8B USD
Have any thoughts about
Resmed Inc?
Write Note

Resmed Inc
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Resmed Inc
Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Resmed Inc
NYSE:RMD
Cash Equivalents
$426.4m
CAGR 3-Years
16%
CAGR 5-Years
20%
CAGR 10-Years
-7%
Becton Dickinson and Co
NYSE:BDX
Cash Equivalents
$1.7B
CAGR 3-Years
-9%
CAGR 5-Years
26%
CAGR 10-Years
-1%
Boston Scientific Corp
NYSE:BSX
Cash Equivalents
$2.5B
CAGR 3-Years
9%
CAGR 5-Years
55%
CAGR 10-Years
26%
Stryker Corp
NYSE:SYK
Cash Equivalents
$3.9B
CAGR 3-Years
15%
CAGR 5-Years
15%
CAGR 10-Years
11%
Abbott Laboratories
NYSE:ABT
Cash Equivalents
$7B
CAGR 3-Years
-9%
CAGR 5-Years
11%
CAGR 10-Years
7%
Intuitive Surgical Inc
NASDAQ:ISRG
Cash Equivalents
$1.8B
CAGR 3-Years
32%
CAGR 5-Years
23%
CAGR 10-Years
14%
No Stocks Found

Resmed Inc
Glance View

Market Cap
35.8B USD
Industry
Health Care

ResMed Inc. is a leading global company dedicated to transforming the lives of individuals suffering from sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Founded in 1989, ResMed has consistently innovated in the development of cutting-edge devices and cloud-connected software that enable patients to monitor their health and improve their quality of life. The company’s flagship products, including CPAP machines and adaptive cloud-based solutions, make it easier for patients to adhere to therapy while providing valuable data to healthcare providers. This commitment to integrating technology with healthcare has positioned ResMed as a key player in the booming health tech industry, appealing to both patients and investors alike. As the demand for effective respiratory therapy solutions continues to grow, driven by rising incidences of sleep disorders and an aging global population, ResMed stands out with its strong market presence and strategic focus on digital health. The company's agile approach allows it to swiftly adapt to changing market dynamics, evidenced by its expansion into software solutions that enhance patient management and clinical outcomes. With a robust balance sheet and a commitment to sustainable growth, ResMed not only offers potential for solid long-term returns but also embodies the principles of value investing that resonate with discerning investors. As the landscape of healthcare evolves, ResMed is poised to remain at the forefront, making it a compelling option for those looking to invest in the future of health technology.

RMD Intrinsic Value
192.96 USD
Overvaluation 21%
Intrinsic Value
Price

See Also

What is Resmed Inc's Cash Equivalents?
Cash Equivalents
426.4m USD

Based on the financial report for Sep 30, 2024, Resmed Inc's Cash Equivalents amounts to 426.4m USD.

What is Resmed Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
-7%

Over the last year, the Cash Equivalents growth was 104%. The average annual Cash Equivalents growth rates for Resmed Inc have been 16% over the past three years , 20% over the past five years , and -7% over the past ten years .

Back to Top